Package leaflet: Information for the user

Irinotecan Mylan 20 mg/ml, concentrate for solution for infusion

Irinotecan hydrochloride trihydrate

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor,nurse or pharmacist.
- This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Irinotecan Mylan is and what it is used for

Your medicine is called Irinotecan Mylan. Irinotecan Mylan belongs to a group of medicines called **cytostatics (anti-cancer medicines).**
Irinotecan Mylan may be used alone or in combination with a number of other medicines used to treat cancer. These combinations may be used to treat **cancer of the large intestine (colon or recum)** where the disease is at an **advanced stage.**
Your doctor may use a combination of Irinotecan Mylan with **5-flurouracil/folinic acid (5FU/FA)** and **bevacizumab** to treat your **cancer of the large intestine (colon or rectum).**
Your doctor may use a combination of Irinotecan Mylan with **capecitabine** with or without **bevacizumab** to treat your **cancer of the colon or rectum.** Your doctor may use a combination of Irinotecan Mylan with **cetuximab** to trate a particular type of **cancer of the large intestine (KRAS wild-type)** which expresses a protein called **EGFR.**

2. What you need to know before you use Irinotecan Mylan

Do not use Irinotecan Mylan

- if you are allergic to **irinotecan hydrochloride** or any of the other ingredients of Irinotecan Mylan.
- if you have or have had **cronic inflammatory bowel** disease or **bowel obstruction.**
- if you are **Pregnant** or **breast feeding** or if you think you might be pregnant.
- if you have **severe liver disease** if you have **severe bone marrow failure.**
- if your general health status does not allow you to carry out general activities of daily living.
- if you are taking **St Johns' Wort (a herbal suplement) Take special care with Irinotecan Mylan.**

Before treatment with Irinotecan Mylan tell your doctor if any of the following apply to you:

- You have **liver problems** or **jaundice**
- You have **kidney problems**
- You have **asthma**
- You have ever received **radiation therapy**
- You experienced **severe diarrhoea** or **fever** after being treated with Irinotecan Mylan before.
- You have **heart problems**
- You **smoke,** have **high blood pressure** or **high cholesterol** as these can increase the risk of heart problems during treatment with Irinotecan Mylan
- You have had or are due to have any **vaccinations**
- You are taking any other medicines. Please see the section below **"Taking other medicines".**

As with all anti-cancer medicines the use of Irinotecan Mylan is associated with a number of side-effects with may be serious. These side-effects require special management to mininmise the risk of complications.

You will be treated by a specialist team experienced in using these kinds of treatments and manging their side effects, which are usullly temporary. However, it is essential that you read the section **"POSSIBLE SIDE EFFECTS"** and follow the instructions carefully if you getany of the symptions described.

Taking Other medicines:

Please tell your doctor if your taking or have recently taken any other medicines, including medicines obtained with out a prescription.

If you received Irinotecan Mylan in combination with either capecitabine, cetuximab or bevacizumad, please make sure that you also read patient information leaflet for each medicine.

Some medicines, when taken at the same time as Irinotecan Mylan, may effect the why Irinotecan Mylan works or Irinotecan Mylan may effect the way they work. Tell your doctor if you are taking any of the following medicines:

- **St. John's Wort (a herbal supplement)**
- **Ketoconazole (an antibiotic)**
- **Rifampicin (an antibiotic)**
- **Carbamazepine (used to treat seizures)**
- **Phenobarbital (used to treat seizures)**
- **Warfarin (an anticoagulant used to thin the blood)**
- **Atazanavir (used to treat HIV)**
- **Ciclosporin or Tacrolimus (used to dampen down your body's immune system)**

If you go into hospital to have an operation, tell the anaesthetist and the medical staff that you are being treated with Irinotecan Mylan and any other medicines your taking.

Pregnancy and breast-feeding

You must **not use Irinotecan Mylan if you are pregnant as it may harm your unborn baby.**

You should also **avoid becoming pregnant while you are being treated with Irinotecan Mylan,**

Men and women should use adequate contraception while being treated with Irinotecan Mylan and for:

- **Up to 1 month after you receive your last dose of Irinotecan Mylan if your female**
- **Up to 3 months after your last dose of Irinotecan Mylan if you are male.**

If you do become pregnant while being treated with Irinotecan Mylan you must inform your doctor **IMMEDIATELY.**

Because Irinotecan Mylan may be harmful to nursing infants, women **must not breast-feed** while being treated with Irinotecan Mylan.

Driving and Using Machines

Irinotecan Mylan may make you feel dizzy or cause visual distrubances. If this happens to you **do not drive or opereate machinary** unit this resolves.

Irinotecan Mylan contains sorbitol and sodium.
This medicine contains 45 mg sorbitol in each millilitre. Sorbitol is a source of fructose. If you have hereditary fructose intolerance (HFI), a rare genetic disorder, you must not receive this medicine. Patients with HFI cannot break down fructose, which may cause serious side effects. You must tell your doctor before receiving this medicine if you have HFI.

This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'

3. How to use Irinotecan Mylan

If you are prescribed Irinotecan Mylan it will only be given to you by doctors or nurses experienced in giving chemotherapy.

Method of administration: Irinotecan Mylan will be given as an infusion into your veins over a period of 30 to 90 minutes.

If you receive Irinotecan Mylan in combination with **cetuximab,** Irinotecan Mylan must not be administered earlier than 1 hour after the end of the **cetuximab** infusion.

Dosage and frequency of administration:
The amount of Irinotecan Mylan you are given will depend on your age, size and general medical condition. It will also depend on any other treatment you may have received for your cancer.

Your doctor will calculate your body surface area in square metres (m^2).

- **If you have previously been treated with 5-fluorouracil you will normally be treated with Irinotecan Mylan alone starting with a dose of 350 mg/m^2 every three weeks.**

- **If you have not had previous chemotherapy you will normally receive 180 mg/ m^2 Irinotecan Mylan every two weeks. This will be followed by folinic acid and 5-fluorouracil.**

These dosages may be adjusted by your doctor depending on your condition and any side-effects you may have.

Duration of treatment:
The number of infusions that you receive will depend on how you are responding to treatment. Your doctor will discuss this with you.

<u>Blood Monitoring</u>
Whilst you are taking Irinotecan Mylan and/or other similar medicines you will have regular blood tests to monitor your treatment and to ensure that there are no untoward adverse effects.

4. Possible side effects

Medicines like Irinotecan Mylan will cause side effects. Your doctor will discuss these side-effects with you and explain the risks and benefits of your treatment.

Some of these side effects must be treated **IMMEDIATELY.**

Please read the following instructions carefully and follow them if you have any of the side-effects listed.

Diarrhoea

Irinotecan Mylan may cause you to have diarrhoea. There are two types of diarrhoea, which can be distinguished when they start. "Early" diarrhoea starts less than 24 hours after the infusion and "delayed" diarrhoea starts more than 24 hours after infusionIf you have **ANY DIARRHOEA** it is **IMPORTANT** that you follow these instructions carefully.

Early diarrhoea

- **If your diarrhoea starts less than 24 hours after the infusion** ("early diarrhoea") you should contact your doctor or nurse **IMMEDIATELY** and they will give you a suitable treatment.

This "early diarrhoea" may be accompanied by other symptoms such as

- sweating
- chills
- abdominal cramps
- watering eyes
- stuffy nose
- visual disturbance
- dizziness
- low blood pressure
- feeling unwell
- feeling weak
- excessive mouth watering
- pupils of the eye get smaller

Tell your doctor or nurse about all symptoms.

Do not use any anti-diarrhoeal treatment that your doctor has given you for "delayed diarrhoea".

Delayed diarrhoea

- **If your diarrhoea starts more than 24 hours** after infusion ("delayed diarrhoea") **you should IMMEDIATELY take any anti-diarrhoeal treatment that the doctor has given you, EXACTLY as he has told you. If you are unsure of what it is, ask your doctor or nurse**

Drink large amounts of rehydration fluids**, IMMEDIATELY** (i.e. water, soda water, fizzy drinks, soup or oral rehydration therapy).

- **You must tell your doctor if** you have nausea and vomiting as well as diarrhoea
- you have any fever as well as the diarrhoea
- you still have diarrhoea 48 hours after starting the diarrhoea treatment

Do not take any treatment for diarrhoea other than that given to you by your doctor or nurse and only drink the fluids described above.

Decrease in white blood cells

Irinotecan Mylan may cause a decrease in the number of some of your white blood cells, which play an important role in fighting infections. This is called **neutropenia.** Your doctor will probably arrange for you have regular blood tests to monitor these white blood cells.

If you have any fever this may be an indication of infection associated with **neutropenia** and requires immediate treatment.

If you have any **fever** and particularly if you also have **diarrhoea**, contact your doctor or nurse **IMMEDIATELY** so that they can give you necessary treatment.

Nausea and vomiting
If you have nausea and/or vomiting contact your doctor or nurse **IMMEDIATELY.**

Breathing difficulties
If you have breathing difficulties contact your doctor or nurse **IMMEDIATELY.**

Other side effects
All medicines can cause allergic reactions. If you experience any of the following conditions please report it to a doctor or nurse **IMMEDIATELY**

- wheeziness
- difficult in breathing
- swelling
- rash or itching (especially affecting the whole body)
- dehydration
- kidney problems
- low blood pressure
- heart problems
- blockage or perforation (a 'hole') in the bowel
- bleeding from the bowel
- inflammation in the bowel
- inflammation of the pancreas
- severe stomach pain
- passing black or blood stained stools
- vomiting blood
- changes in laboratory tests

If you receive Irinotecan Mylan in combination with **cetuximab**, some of the side effects you may experience can also be related to this combination. Such side effects may include **an acne-like rash.** Therefore, please make sure that you also read the package leaflet for **cetuximab**. If you receive Irinotecan Mylan in combination with **capecitabine**, some of the side effects you may experience can also be related to this combination. Such side effects may include: very common blood clots, common allergic reactions, heart attack and fever in patients with a low white blood cell count. Therefore, please make sure that you also read the package leaflet for **capecitabine**.

If you receive Irinotecan Mylan in combination with **capecitabine** and **bevacizumab**, some of the side effects you may experience can also be related to this combination. Such side effects include: low white blood cell count, blood clots, high blood pressure and heart attack. Therefore, please make sure that you also read the package leaflet for **capecitabine** and **bevacizumab**.

Other side effects which may occur when you are treated with Irinotecan Mylan are:

- hair loss
- fatigue
- loss of appetite
- mild allergic skin reactions
- mild stomach pains
- muscular cramps and twitches

- pins and needles
- constipation
- inflammation at the injection site
- mouth ulcers
- temporary speech disorders
- high blood pressure
- fungal infections
- Viral infections
- Fatty liver disease

If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or nurse immediately.

Reporting of side effects
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist immediately. You can also report side effects directly via HPRA Pharmacovigilance. Website: www.hpra.ie. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Irinotecan Mylan

Keep out of the reach and sight of children.

For single use only.

Do not use this medicinal product after the expiry date which is stated on the carton and on the glass after EXP. The expiry date refers to the last day of that month.

This medicinal product does not require any special storage conditions.

After dilution
The medicine will be given to you within 24 hours of dilution. The diluted solution may have been stored at 5°C and 25°C.

6. Contents of the pack and other information

What Irinotecan Mylan contains

The active substance is **irinotecan hydrochloride** trihydrate.
- One ml of concentrate contains 20 mg irinotecan hydrochloride trihydrate equivalent to 17.33 mg of irinotecan.
  - One 2 ml vial contains 40 mg irinotecan hydrochloride trihydrate.
  - One 5 ml vial contains 100 mg irinotecan hydrochloride trihydrate.
  - One 15 ml vial contains 300 mg irinotecan hydrochloride trihydrate.
  - One 25 ml vial contains 500 mg irinotecan hydrochloride trihydrate.

The other ingredients are sorbitol, lactic acid, sodium hydroxide, hydrochloric acid and water for injections. See section 2, 'Irinotecan Mylan contains sorbitol and sodium'.

What Irinotecan Mylan looks like and contents of the pack

Irinotecan Mylan is a pale yellow color clear aqueous solution, free from visible particles. pH 3.0 to 3.8.

40 mg/2 ml:
Type I flint amber colored glass vial, with a rubber stopper (bromo butyl omniflex plus coated rubber stopper) and sealed with an aluminium flip-off Dark blue colour seals.

100 mg/5 ml:
Type I flint amber colored glass vial, with a rubber stopper (bromo butyl omniflex plus coated rubber stopper) and sealed with an aluminium flip-off Light blue colour seals.

300 mg/15 ml:
Type I flint amber colored glass vial, with a rubber stopper (bromo butyl omniflex plus coated rubber stopper) and sealed with an aluminium flip-off Dark blue colour seals.

500 mg/25 ml:
Type I amber colored glass vial, with a rubber stopper (bromo butyl omniflex plus coated rubber stopper) and sealed with an aluminium flip-off Dark blue colour seals.

Pack sizes:

40 mg/2 ml: 1 vial, 5 vials, 10 vials
100 mg/5 ml: 1 vial, 5 vials, 10 vials
300 mg/15 ml: 1 vial
500 mg/25 ml: 1 vial

Not all pack sizes may be marketed

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder
McDermott Laboratories Ltd. T/A Gerard Laboratories
35/36 Baldoyle Industrial Estate,
Grange Road,
Dublin 13,
Ireland

Manufacturer
Wave Pharma Limited
4th Floor Cavendish House, 369 Burnt Oak,
Broadway, Edgware
Middlesex HA85AW
United Kingdom

and/or

Drehm Pharma GmbH
Hietzinger Hauptstraße 37/2
1130 Vienna, Austria

This medicinal product is authorised in the Member States of the EEA under the following names:

Austria	Irinotecan Mylan 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung
Germany	Irinotecan Mylan 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung
France	Irinotecan Mylan Pharma 20 mg/ml solution à diluer pour perfusion
Ireland	Irinotecan Mylan 20 mg/ml concentrate for solution for infusion
Malta	Irinotecan Mylan 20 mg/ml concentrate for solution for infusion

Netherlands	Irinotecan HCl-trihydraat Mylan20 mg/ml concentraat voor oplossing voor infusie
Romania	Irinotecan Mylan 20 mg/ml concentrat pentru soluţie perfuzabilă
United Kingdom	Irinotecan 20 mg/ml concentrate for solution for infusion

This leaflet was last revised in 10/2020.

The following information is intended for medical or healthcare professionals only:

Instruction for personnel regarding safe handling of Irinotecan Mylan

Like all anti-neoplastic substances, irinotecan must be prepared and handled carefully. The use of protective glasses, mask and gloves is required.

If Irinotecan Mylan comes into contact with your skin, wash it off immediately and thoroughly with soap and water. If Irinotecan Mylan comes into contact with your mucous membranes, wash it off immediately and thoroughly with water.

As with all injectable drugs, Irinotecan Mylan must be prepared under aseptic conditions.

If a clouding or condensation is visible in the vial or after dilution of the concentrate, the medicine may not be used and must be disposed of.

Preparation of the solution for infusion
As with any other injectable drugs, Irinotecan Mylan solution for infusion must be prepared aseptically.

If you observe any precipitate in the vial or solution for infusion, discard the product according to standard procedures for cytotoxic agents.

Aseptically withdraw the calculated amount of Irinotecan Mylan concentrate for solution for infusion from the vial into a syringe and transfer into a 250 ml infusion bag or bottle containing either 0.9% (w/v) sodium chloride solution or 5% (w/v) glucose infusion solution. Mix the solution for infusion in the infusion bag or bottle thoroughly by manual rotation.

Do not mix with other medicines.

Shelf life
The diluted Irinotecan Mylan solution is physically and chemically stable up to 28 days as a solution for infusion (9% (w/v) sodium chloride solution and 5% (w/v) glucose solution) when stored in LDPE or PVC at 5°C or at 30°C when protected from light and humidity.

When the diluted solution is not stored and protected from light, it is physically and chemically stable up to 3 days.

From a microbiological viewpoint, immediate use is recommended. If the product is not used immediately after dilution, the storage times and conditions are the responsibility of the user and would normally not be longer than 24 hours at 25°C, unless the dilution took place in controlled aseptic conditions.

Warnings against some visible signs of deterioration
Do not use Irinotecan Mylan if you notice a precipitate in the vials or the diluted solution. In this case, the product should be discarded according to the standard procedures for disposal of cytotoxic waste. Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

Administration
For information on administration, please read the Summary of Product Characteristics for Irinotecan Mylan.

Disposal
Any unused medicinal product or waste material should be disposed of in accordance with local requirement.